BioCentury | Mar 30, 2021
Deals

Deerfield’s growing umbrella: Data Byte

...Bay City Capital to support pre-IND stage compounds developed by Tri-Institutional Therapeutics Discovery Institute members Memorial Sloan Kettering Cancer Center...
BioCentury | Mar 22, 2021
Management Tracks

José Baselga, AstraZeneca cancer leader and renowned breast cancer researcher, dies at 61

...a compound he helped develop while at Memorial Sloan Kettering Cancer Center...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...by Charlene Liao, Guo-Liang YuAcademic collaborators: The University of Texas, Albert Einstein College of Medicine, Memorial Sloan Kettering...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

...By Claire Quang, Staff Writer DISEASE CATEGORY: CancerINDICATION: Melanoma; lung cancerA Yale University and Memorial Sloan Kettering Cancer Center team led...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...In November, it signed a deal with Memorial Sloan Kettering Cancer Center...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...builds machine-learning algorithms that analyze digitized pathology images for diagnostics. The technology was developed at Memorial Sloan Kettering Cancer Center...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...United Therapeutics Corp. (NASDAQ:UTHR) for $105 million. Memorial Sloan Kettering Cancer Center...
...Corp. Cellenkos Inc. Cullinan Management Inc. United Therapeutics Corp. Y-mAbs Therapeutics Inc. Memorial Sloan Kettering Cancer Center United...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...T cell platform and technologies licensed from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...could lead to full approval of the humanized mAb against GD2. Y-mAbs licensed Danyelza from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
...of drugs.” Steve Usdin U.S. Food and Drug Administration (FDA) Memorial Sloan Kettering Cancer Center Merck...
Items per page:
1 - 10 of 692
BioCentury | Mar 30, 2021
Deals

Deerfield’s growing umbrella: Data Byte

...Bay City Capital to support pre-IND stage compounds developed by Tri-Institutional Therapeutics Discovery Institute members Memorial Sloan Kettering Cancer Center...
BioCentury | Mar 22, 2021
Management Tracks

José Baselga, AstraZeneca cancer leader and renowned breast cancer researcher, dies at 61

...a compound he helped develop while at Memorial Sloan Kettering Cancer Center...
BioCentury | Feb 26, 2021
Emerging Company Profile

Immune-Onc building broad pipeline of myeloid checkpoint inhibitors

...by Charlene Liao, Guo-Liang YuAcademic collaborators: The University of Texas, Albert Einstein College of Medicine, Memorial Sloan Kettering...
BioCentury | Feb 26, 2021
Distillery Therapeutics

Zelboraf-based PROTAC for melanoma, lung cancer expressing BRAF mutations

...By Claire Quang, Staff Writer DISEASE CATEGORY: CancerINDICATION: Melanoma; lung cancerA Yale University and Memorial Sloan Kettering Cancer Center team led...
BioCentury | Feb 10, 2021
Deals

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

...In November, it signed a deal with Memorial Sloan Kettering Cancer Center...
BioCentury | Jan 15, 2021
Product Development

Paige to accelerate development, adoption of digital cancer diagnostic with $100M series C

...builds machine-learning algorithms that analyze digitized pathology images for diagnostics. The technology was developed at Memorial Sloan Kettering Cancer Center...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

...United Therapeutics Corp. (NASDAQ:UTHR) for $105 million. Memorial Sloan Kettering Cancer Center...
...Corp. Cellenkos Inc. Cullinan Management Inc. United Therapeutics Corp. Y-mAbs Therapeutics Inc. Memorial Sloan Kettering Cancer Center United...
BioCentury | Dec 7, 2020
Deals

Adding first CAR T to growing cell therapy unit, Bayer picks Atara’s allogeneic program targeting mesothelin

...T cell platform and technologies licensed from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 25, 2020
Product Development

Nov. 25 Quick Takes: FDA approves Y-mAbs’ Danyelza; plus NIH’s ACTT-4; COVAXX, Urovant, SomaLogic, Eluminex and Liquidia

...could lead to full approval of the humanized mAb against GD2. Y-mAbs licensed Danyelza from Memorial Sloan Kettering Cancer Center...
BioCentury | Nov 21, 2020
Politics, Policy & Law

Fate of Trump’s 11th hour drug price rules uncertain

...Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center...
...of drugs.” Steve Usdin U.S. Food and Drug Administration (FDA) Memorial Sloan Kettering Cancer Center Merck...
Items per page:
1 - 10 of 692